Novo Nordisk has launched its once-weekly diabetes and weight-management drug Ozempic in India. The semaglutide-based GLP-1 agonist improves glycaemic control, supports weight loss and may reduce cardiovascular and kidney risks. Prices start at Rs 8,800 per month for the lowest dose

Hyderabad: Novo Nordisk on Friday launched its blockbuster anti-diabetic and anti-obesity drug Ozempic in India. The drug is a once-weekly GLP-1 Receptor Agonist (GLP-1 RA) indicated as an adjunct to diet and exercise for adults living with uncontrolled Type 2 Diabetes Mellitus (T2DM).

Ozempic’s active ingredient, semaglutide, works as a GLP-1 receptor agonist to help improve glycaemic control and reduce HbA1c and acts on areas of the brain that control hunger and regulate food intake, supporting weight-loss

See Full Page